<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782288</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-003456-01</org_study_id>
    <nct_id>NCT00782288</nct_id>
  </id_info>
  <brief_title>Phase II Study of Digitoxin to Treat Cystic Fibrosis</brief_title>
  <official_title>Phase II Study of Digitoxin to Treat Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pam Zeitlin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the inflammatory effects of digitoxin on IL-8 and neutrophil counts
      in induced sputum in stable Cystic Fibrosis (CF) patients and the pharmacokinetics of
      digitoxin in serum.

      Funding Source-FDA OOPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted as a randomized, double blind, placebo-controlled, repeat dosing
      trial evaluating the effects of 28 days of digitoxin on IL-8 and neutrophil concentrations in
      induced sputum in subjects with mild to moderate cystic fibrosis lung disease. Twenty-four
      total patients will be randomized into 3 groups of 8 subjects each (0.05 mg or 0.1 mg
      digitoxin or a placebo).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients.</measure>
    <time_frame>42 days (Day 1 to Day 42)</time_frame>
    <description>The Il-8 measurements of sputum digitoxin levels for each group is shown for 5 days (Days 1, 14, 21, 28 and 42).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Il-8 (Interleukin 8) Levels From Day 28 Minus Day 1 (Treatment Period).</measure>
    <time_frame>28 days (Day 28 minus Day 1)</time_frame>
    <description>Change in Il-8 values are expressed as a change in log 10 Il-8 pg/mL from Day 28 minus Day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Digitoxin on Neutrophil Counts in Induced Sputum in Stable Cystic Fibrosis (CF) Patients.</measure>
    <time_frame>42 days (Day 1- Day 42)</time_frame>
    <description>The neutrophil counts were measured in the induced sputum of participants in each group on study 5 days (Days 1, 14, 21, 28 and 42).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Neutrophil Cell Count Day 28 Minus Day 1 (Treatment Period).</measure>
    <time_frame>28 days (Day 28 minus Day 1)</time_frame>
    <description>The change in log 10 neutrophil cell count from Day 28 minus Day 1 (during the treatment period) expressed as log (10^4 neutrophil/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Digitoxin in Serum in Stable CF Patients.</measure>
    <time_frame>Serum PK on Days 1 (pre-dose), 7, 14, 21 and 42</time_frame>
    <description>Digitoxin serum levels were drawn on Days 1 (pre-dose), 7, 14, 21 and 42. The range of digitoxin levels for each visit is listed and the number of subjects who had that level are marked by group (placebo, low dose and high dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Indices Including Change in FEV1 in Stable CF Patients.</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Safety indices included changes in FEV1 (forced expiratory volume in 1 second), changes in WBC (white blood cell count), alterations in ECG and sputum microbiology. The median changes in FEV1 are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Quality of Life Scores, for Each Domain, From Day 1 to Day 42 Using the Cystic Fibrosis Questionnaire Revised (CFQ-R).</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>CFQ-R is a disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms. Developed specifically for use in patients with a diagnosis of cystic fibrosis. There are 9 Quality of life domains: physical, role/school, vitality, emotion, social, body image, eating, treatment burden, health perceptions and 3 symptom scales: weight, respiratory, and digestion.
Scaling of items is done via 5 distinct 4-point Likert scales. Scores for each domain; after recoding, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health. Based on clinician judgment of global clinical change, a moderate change was a standardized effect size of 0.50 units and an important change was a standardized effect size of 0.80 units evaluating pre- and post-treatment for CF exacerbation. Mean changes in CFQ-R Scores by Group were evaluated between Visit 6 and Visit 1, by Domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WBC (White Blood Cell) Count by Group During Treatment Period</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Safety indices included changes in FEV1 (lung function), changes in WBC, alterations in ECG and sputum microbiology. There were no significant alterations in the ECG in any subjects over the course of the study. There were no subjects who acquired multiple resistant changes in microbiology of sputum and no acquisition of B. cepacia in any subjects. Therefore, these data were not analyzed. The median changes in FEV1 and median changes in WBC, ESR and CRP are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in C Reactive Protein (CRP) During Treatment.</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Median changes in CRP and IQR were assessed from serum samples collected at Visits 1,3, 4 and 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Erythrocyte Sedimentation Rate (ESR) During Treatment Period.</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Median change in serum ESR (mm/hr) and IQR was calculated from Treatment Period (28 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CF Subjects With Microarray Results From Nasal Epithelial Cells to Measure the Effect of Digitoxin on Gene Expression.</measure>
    <time_frame>Day 0 and Day 28</time_frame>
    <description>Rhinoprobe was used to collect nasal epithelial cells. The cells were collected pre and post-treatment and placed in Trizol for RNA isolation then used to measure the effect of digitoxin on gene expression. The full set of microarray data has been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). The accession number for that data is GSE76347 (data available Dec 2018).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Alterations in ECG Readings</measure>
    <time_frame>28 days</time_frame>
    <description>Safety indices included an assessment for the number of clinically significant alterations in the subjects ECG readings from Day 1 to Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Changes in the Microbiology of Sputum in Subjects</measure>
    <time_frame>28 days</time_frame>
    <description>Count of clinically significant changes in sputum microbiology during the Treatment phase (Day 1 to Day 28) to include any new acquisition of B. cepacia or new acquisition of any multiple resistant organism.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low dose 0.05mg digitoxin given once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>higher dose 0.1mg digitoxin daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo given daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>digitoxin</intervention_name>
    <description>0.05mg tabs, once daily for 28 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>digitoxin</intervention_name>
    <description>0.1mg pills, once daily for 28 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>pill taken once daily for 28 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female 18-45 years of age

          -  Confirmed diagnosis of CF based on the following criteria:positive sweat chloride &gt; or
             = 60 mEq/liter (by pilocarpine iontophoresis) and/or a genotype with two identifiable
             mutations consistent with CF

          -  FEV1 &gt; or = 40% predicted value at screening

          -  Weight &gt; 45 kg at Screening and Visit 1 (dosing)

          -  Clinically stable with no evidence of acute upper or lower respiratory tract infection
             or current pulmonary exacerbation (see Appendix II) or treatment of a pulmonary
             exacerbation within the 14 days prior to Screen Visit. Subject may rescreen 14 days
             after they complete treatment for a pulmonary exacerbation, if healthy at that time.

          -  Ability to perform Spirometry.

          -  Ability to understand and sign a written informed consent and comply with the
             requirements of the study.

        Exclusion Criteria:

          -  Use of an investigational agent within the 4-week period prior to Screen visit.

          -  Use of a medication with anti-neutrophil or anti-inflammatory effect or those known to
             have an effect on inflammatory outcomes [azithromycin, gentamicin, amikacin, colistin,
             ibuprofen, celecoxib, or other NSAIDs, prednisone or other corticosteroids(systemic or
             inhaled), such as Advair, cromolyn (Intal®), montelukast (Singulair®), zafirlukast
             (Accolate®), zileuton (Zyflo®), and any immunosuppressive agent within the 4 weeks
             prior to Visit #1, Day 1 and until their participation in the study ends (after Visit
             6). See NOTE at end of exclusionary criteria for subjects on oral antibiotic therapy.

          -  Use of topical nasal steroid products for at least 2 weeks prior to study drug
             administration and discontinued use until after the nasal cell collection at Day 28.

          -  Inability or unwillingness to stop macrolide antibiotics 4 weeks prior to Day 1 until
             their participation in the study ends. Prior use of macrolide antibiotics, including
             those for maintenance therapy will not exclude the subject from participation.

          -  History of significant cardiac disease or cardiac arrhythmia

          -  Presence of an arrhythmia identified on screening ECG or 24 hour holter monitor

          -  Pulmonary hypertension

          -  History of significant cardiac disease or cardiac arrhythmia

          -  Presence of a clinically significant arrhythmia identified on screening ECG or 24 hour
             holter monitor.

          -  Pulmonary hypertension

          -  Burkholderia species in sputum within 2 years or at Screen visit

          -  Drugs known to interact with digitoxin including phenobarbital, amphotericin B,
             rifampicin, diltiazem, and verapamil or drugs that would potentiate potassium loss
             (certain diuretics or excessive laxative use, defined as more than twice daily use of
             miralax).

          -  Unwillingness to use beta-agonists (or levalbuterol) prior to induced sputum
             procedures.

          -  Oxygen saturation &lt; 92% on room air at Screen visit

          -  Pregnant, breastfeeding, or unwilling to use an effective form of birth control for
             the duration of the study

          -  History of significant hemoptysis &gt; or = 60cc per episode during the 30 days prior to
             Screening visit

          -  Significant history of hepatic, cardiovascular, renal, neurological, hematologic, or
             peptic ulcer disease

          -  SGOT (ALT) or SGPT (AST) &gt; 3 times the upper limit of normal at Screen, documented
             biliary cirrhosis, or portal hypertension

          -  Creatinine &gt; 1.8 mg/dL at Screen

          -  Inability to swallow pills

          -  Potassium, serum &lt;3.3 mEq/L at screening

          -  Known inability to produce sputum (if unable to expectorate, must be able to produce
             an induced sputum sample at screening).

          -  Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the subject or the quality of the data NOTE: For subjects on
             continuous antibiotic therapy for at least 6 months one continuous antibiotic or
             alternating two different antibiotics, they can maintain their current therapy. If the
             subject is alternating between two different inhaled antibiotics each month, Visit 1
             should coincide with the &quot;on&quot; cycle of one of the inhaled antibiotics for consistency
             during the treatment period. For subjects on alternate month TOBI®, colistin or
             Cayston therapy, the &quot;off&quot; cycle must coincide with the Treatment Phase of the study.
             Subjects should be scheduled for Screening Visit during their one-month &quot;on&quot; period,
             and may resume taking TOBI®, colistin or Cayston after completion of Visit 6 (Day 42)
             or early termination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela L Zeitlin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University, School of Medicine, Pediatric Pulmonary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hopkinscf.org</url>
    <description>Johns Hopkins Cystic Fibrosis website</description>
  </link>
  <link>
    <url>http://www.cff.org</url>
    <description>Cystic Fibrosis Foundation website</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>October 14, 2015</results_first_submitted>
  <results_first_submitted_qc>January 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 22, 2016</results_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Pam Zeitlin</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>digitoxin</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>cytokines</keyword>
  <keyword>gene expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digitoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants were recruited from the Johns Hopkins University in Baltimore, Maryland. The first participant was enrolled on October 13, 2010 and the last participant was enrolled on May 6, 2014. All study visits were completed as of June 2014. There was a DSMB safety review prior to enrolling any subjects into the higher dose group (0.1 mg).</recruitment_details>
      <pre_assignment_details>Participants were all consented on a Johns Hopkins IRB approved consent form and screened 2 or 4 weeks prior to enrollment. Enrollment was contingent on meeting all inclusion/exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
        </group>
        <group group_id="P2">
          <title>Low Dose 0.05mg Digitoxin</title>
          <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
        </group>
        <group group_id="P3">
          <title>Higher Dose 0.1mg Digitoxin</title>
          <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
        </group>
        <group group_id="B2">
          <title>Low Dose 0.05 mg Digitoxin</title>
          <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
        </group>
        <group group_id="B3">
          <title>Higher Dose 0.1mg Digitoxin</title>
          <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" lower_limit="18.2" upper_limit="39.7"/>
                    <measurement group_id="B2" value="23.5" lower_limit="18.2" upper_limit="37.7"/>
                    <measurement group_id="B3" value="30.3" lower_limit="19.8" upper_limit="42.8"/>
                    <measurement group_id="B4" value="26.2" lower_limit="18.2" upper_limit="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients.</title>
        <description>The Il-8 measurements of sputum digitoxin levels for each group is shown for 5 days (Days 1, 14, 21, 28 and 42).</description>
        <time_frame>42 days (Day 1 to Day 42)</time_frame>
        <population>Sputum was collected for Il-8 biomarkers on Days 1,14, 21, 28 during the treatment phase and at Day 42. Measures were compared between Baseline, Treatment and Recovery periods to determine if changes from baseline differed between placebo and the two doses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05 mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients.</title>
          <description>The Il-8 measurements of sputum digitoxin levels for each group is shown for 5 days (Days 1, 14, 21, 28 and 42).</description>
          <population>Sputum was collected for Il-8 biomarkers on Days 1,14, 21, 28 during the treatment phase and at Day 42. Measures were compared between Baseline, Treatment and Recovery periods to determine if changes from baseline differed between placebo and the two doses.</population>
          <units>log 10 (pg/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-8 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="4.15" upper_limit="5.12"/>
                    <measurement group_id="O2" value="4.96" lower_limit="4.4" upper_limit="5.18"/>
                    <measurement group_id="O3" value="5.04" lower_limit="4.58" upper_limit="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" lower_limit="4.21" upper_limit="5.34"/>
                    <measurement group_id="O2" value="4.89" lower_limit="4.50" upper_limit="5.01"/>
                    <measurement group_id="O3" value="5.01" lower_limit="4.66" upper_limit="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" lower_limit="4.21" upper_limit="5.38"/>
                    <measurement group_id="O2" value="4.77" lower_limit="4.64" upper_limit="4.89"/>
                    <measurement group_id="O3" value="5.17" lower_limit="4.66" upper_limit="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" lower_limit="4.49" upper_limit="5.38"/>
                    <measurement group_id="O2" value="4.79" lower_limit="4.49" upper_limit="4.91"/>
                    <measurement group_id="O3" value="5.20" lower_limit="4.68" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="4.22" upper_limit="5.06"/>
                    <measurement group_id="O2" value="4.74" lower_limit="4.62" upper_limit="5.04"/>
                    <measurement group_id="O3" value="4.97" lower_limit="4.43" upper_limit="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Measures were compared between Baseline, Treatment &amp; Recovery periods to determine if changes from baseline differed between placebo and the two digitoxin dose levels. Kruskal-Wallis equity of population rank test was performed on the changes Day 28 minus Day 1. To compare the change from baseline to treatment period between the two arms, a Wilcoxon rank sum test was performed. To determine whether induced sputum Il-8 returned to baseline at the final visit, a one sample sign test was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) of Digitoxin in Serum in Stable CF Patients.</title>
        <description>Digitoxin serum levels were drawn on Days 1 (pre-dose), 7, 14, 21 and 42. The range of digitoxin levels for each visit is listed and the number of subjects who had that level are marked by group (placebo, low dose and high dose).</description>
        <time_frame>Serum PK on Days 1 (pre-dose), 7, 14, 21 and 42</time_frame>
        <population>Subjects had serum digitoxin levels drawn at Day 1 (pre-dose) with no levels observed, as expected. Digitoxin was drawn on Day 7, 14, 21 and 42 to determine the number of subjects with a detectable level of digitoxin (ng/mL) in serum by group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) of Digitoxin in Serum in Stable CF Patients.</title>
          <description>Digitoxin serum levels were drawn on Days 1 (pre-dose), 7, 14, 21 and 42. The range of digitoxin levels for each visit is listed and the number of subjects who had that level are marked by group (placebo, low dose and high dose).</description>
          <population>Subjects had serum digitoxin levels drawn at Day 1 (pre-dose) with no levels observed, as expected. Digitoxin was drawn on Day 7, 14, 21 and 42 to determine the number of subjects with a detectable level of digitoxin (ng/mL) in serum by group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7, digitoxin level 5.6 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, digitoxin level 6 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, digitoxin level 6.4 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, digitoxin level 6.9 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, digitoxin level 7.8 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, digitoxin level none detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level 10 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level 11 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level 13 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level 6.8 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level 6.9 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level 7.3 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level 7.5 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level 8.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level 9.3 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level 9.4 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, digitoxin level none detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 10 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 11 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 12 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 13 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 14 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 15 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 4 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 5 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 6 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 6.4 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 6.5 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 6.9 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level 7.5 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, digitoxin level none detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42, digitoxin level 5 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42, digitoxin level none detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Indices Including Change in FEV1 in Stable CF Patients.</title>
        <description>Safety indices included changes in FEV1 (forced expiratory volume in 1 second), changes in WBC (white blood cell count), alterations in ECG and sputum microbiology. The median changes in FEV1 are reported.</description>
        <time_frame>Baseline and Day 28</time_frame>
        <population>Median changes in FEV1 in L by group for the 28 days of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Indices Including Change in FEV1 in Stable CF Patients.</title>
          <description>Safety indices included changes in FEV1 (forced expiratory volume in 1 second), changes in WBC (white blood cell count), alterations in ECG and sputum microbiology. The median changes in FEV1 are reported.</description>
          <population>Median changes in FEV1 in L by group for the 28 days of treatment.</population>
          <units>liters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" lower_limit="-0.37" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.05" upper_limit="0.13"/>
                    <measurement group_id="O3" value="-0.02" lower_limit="-0.14" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Quality of Life Scores, for Each Domain, From Day 1 to Day 42 Using the Cystic Fibrosis Questionnaire Revised (CFQ-R).</title>
        <description>CFQ-R is a disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms. Developed specifically for use in patients with a diagnosis of cystic fibrosis. There are 9 Quality of life domains: physical, role/school, vitality, emotion, social, body image, eating, treatment burden, health perceptions and 3 symptom scales: weight, respiratory, and digestion.
Scaling of items is done via 5 distinct 4-point Likert scales. Scores for each domain; after recoding, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health. Based on clinician judgment of global clinical change, a moderate change was a standardized effect size of 0.50 units and an important change was a standardized effect size of 0.80 units evaluating pre- and post-treatment for CF exacerbation. Mean changes in CFQ-R Scores by Group were evaluated between Visit 6 and Visit 1, by Domain.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>Mean change in CFQ-R scores from Visit 1 to Visit 6, by domain.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Quality of Life Scores, for Each Domain, From Day 1 to Day 42 Using the Cystic Fibrosis Questionnaire Revised (CFQ-R).</title>
          <description>CFQ-R is a disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms. Developed specifically for use in patients with a diagnosis of cystic fibrosis. There are 9 Quality of life domains: physical, role/school, vitality, emotion, social, body image, eating, treatment burden, health perceptions and 3 symptom scales: weight, respiratory, and digestion.
Scaling of items is done via 5 distinct 4-point Likert scales. Scores for each domain; after recoding, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health. Based on clinician judgment of global clinical change, a moderate change was a standardized effect size of 0.50 units and an important change was a standardized effect size of 0.80 units evaluating pre- and post-treatment for CF exacerbation. Mean changes in CFQ-R Scores by Group were evaluated between Visit 6 and Visit 1, by Domain.</description>
          <population>Mean change in CFQ-R scores from Visit 1 to Visit 6, by domain.</population>
          <units>mean change of scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.21" spread="8.55"/>
                    <measurement group_id="O2" value="-14.58" spread="17.11"/>
                    <measurement group_id="O3" value="-2.60" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="7.72"/>
                    <measurement group_id="O2" value="-1.04" spread="5.34"/>
                    <measurement group_id="O3" value="1.04" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="5.89"/>
                    <measurement group_id="O2" value="4.17" spread="6.30"/>
                    <measurement group_id="O3" value="1.04" spread="20.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.83" spread="12.57"/>
                    <measurement group_id="O2" value="-5.00" spread="17.73"/>
                    <measurement group_id="O3" value="4.17" spread="13.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="9.36"/>
                    <measurement group_id="O2" value="-5.56" spread="6.64"/>
                    <measurement group_id="O3" value="-4.17" spread="15.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="14.47"/>
                    <measurement group_id="O2" value="-4.17" spread="22.17"/>
                    <measurement group_id="O3" value="8.33" spread="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="11.01"/>
                    <measurement group_id="O2" value="-1.39" spread="3.93"/>
                    <measurement group_id="O3" value="-1.39" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="9.27"/>
                    <measurement group_id="O2" value="6.94" spread="11.79"/>
                    <measurement group_id="O3" value="5.56" spread="8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="9.27"/>
                    <measurement group_id="O2" value="4.17" spread="5.75"/>
                    <measurement group_id="O3" value="-4.17" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="12.50" spread="17.25"/>
                    <measurement group_id="O3" value="-0.00" spread="17.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.78" spread="13.61"/>
                    <measurement group_id="O2" value="2.78" spread="13.28"/>
                    <measurement group_id="O3" value="-6.94" spread="22.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digestion Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.72" spread="12.51"/>
                    <measurement group_id="O2" value="4.17" spread="10.18"/>
                    <measurement group_id="O3" value="-5.56" spread="16.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in WBC (White Blood Cell) Count by Group During Treatment Period</title>
        <description>Safety indices included changes in FEV1 (lung function), changes in WBC, alterations in ECG and sputum microbiology. There were no significant alterations in the ECG in any subjects over the course of the study. There were no subjects who acquired multiple resistant changes in microbiology of sputum and no acquisition of B. cepacia in any subjects. Therefore, these data were not analyzed. The median changes in FEV1 and median changes in WBC, ESR and CRP are reported.</description>
        <time_frame>Baseline and Day 28</time_frame>
        <population>Safety indices included changes in WBC during treatment for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in WBC (White Blood Cell) Count by Group During Treatment Period</title>
          <description>Safety indices included changes in FEV1 (lung function), changes in WBC, alterations in ECG and sputum microbiology. There were no significant alterations in the ECG in any subjects over the course of the study. There were no subjects who acquired multiple resistant changes in microbiology of sputum and no acquisition of B. cepacia in any subjects. Therefore, these data were not analyzed. The median changes in FEV1 and median changes in WBC, ESR and CRP are reported.</description>
          <population>Safety indices included changes in WBC during treatment for each group.</population>
          <units>K/cu mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-510.28" lower_limit="-2775.00" upper_limit="350.92"/>
                    <measurement group_id="O2" value="-0.98" lower_limit="-680.00" upper_limit="930.00"/>
                    <measurement group_id="O3" value="-0.13" lower_limit="-2130.63" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Il-8 (Interleukin 8) Levels From Day 28 Minus Day 1 (Treatment Period).</title>
        <description>Change in Il-8 values are expressed as a change in log 10 Il-8 pg/mL from Day 28 minus Day 1.</description>
        <time_frame>28 days (Day 28 minus Day 1)</time_frame>
        <population>For change in Il-8 from Day 28 minus Day 1, a Kruskal-Wallis equality of populations rank was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Il-8 (Interleukin 8) Levels From Day 28 Minus Day 1 (Treatment Period).</title>
          <description>Change in Il-8 values are expressed as a change in log 10 Il-8 pg/mL from Day 28 minus Day 1.</description>
          <population>For change in Il-8 from Day 28 minus Day 1, a Kruskal-Wallis equality of populations rank was performed.</population>
          <units>log10 (pg/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.06" upper_limit="0.40"/>
                    <measurement group_id="O2" value="-0.13" lower_limit="-0.23" upper_limit="0.16"/>
                    <measurement group_id="O3" value="0.04" lower_limit="-0.24" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Digitoxin on Neutrophil Counts in Induced Sputum in Stable Cystic Fibrosis (CF) Patients.</title>
        <description>The neutrophil counts were measured in the induced sputum of participants in each group on study 5 days (Days 1, 14, 21, 28 and 42).</description>
        <time_frame>42 days (Day 1- Day 42)</time_frame>
        <population>Neutrophil cell counts were compared between Baseline, Treatment and Recovery periods to determine if changes from baseline differed between the placebo and the two digitoxin dose levels.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05 mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Digitoxin on Neutrophil Counts in Induced Sputum in Stable Cystic Fibrosis (CF) Patients.</title>
          <description>The neutrophil counts were measured in the induced sputum of participants in each group on study 5 days (Days 1, 14, 21, 28 and 42).</description>
          <population>Neutrophil cell counts were compared between Baseline, Treatment and Recovery periods to determine if changes from baseline differed between the placebo and the two digitoxin dose levels.</population>
          <units>log 10 (neutrophil cells/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" lower_limit="1.89" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.82" lower_limit="1.88" upper_limit="3.08"/>
                    <measurement group_id="O3" value="2.93" lower_limit="2.35" upper_limit="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" lower_limit="2.18" upper_limit="2.92"/>
                    <measurement group_id="O2" value="2.26" lower_limit="1.35" upper_limit="2.91"/>
                    <measurement group_id="O3" value="2.71" lower_limit="2.26" upper_limit="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" lower_limit="2.44" upper_limit="3.35"/>
                    <measurement group_id="O2" value="2.23" lower_limit="1.52" upper_limit="2.62"/>
                    <measurement group_id="O3" value="2.88" lower_limit="1.90" upper_limit="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" lower_limit="2.16" upper_limit="3.06"/>
                    <measurement group_id="O2" value="2.16" lower_limit="0.83" upper_limit="2.64"/>
                    <measurement group_id="O3" value="2.77" lower_limit="1.97" upper_limit="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" lower_limit="2.27" upper_limit="2.81"/>
                    <measurement group_id="O2" value="2.06" lower_limit="1.58" upper_limit="2.35"/>
                    <measurement group_id="O3" value="2.82" lower_limit="2.00" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline,Treatment and Recovery periods were compared to determine if changes from baseline differed between placebo and the two digitoxin doses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Neutrophil Cell Count Day 28 Minus Day 1 (Treatment Period).</title>
        <description>The change in log 10 neutrophil cell count from Day 28 minus Day 1 (during the treatment period) expressed as log (10^4 neutrophil/mL).</description>
        <time_frame>28 days (Day 28 minus Day 1)</time_frame>
        <population>The change in neutrophil cell count from Day 1 to Day 28 was performed using a Kruskal-Wallis equality of populations rank test. The cells counts are expressed as log 10 (neutrophil cell/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neutrophil Cell Count Day 28 Minus Day 1 (Treatment Period).</title>
          <description>The change in log 10 neutrophil cell count from Day 28 minus Day 1 (during the treatment period) expressed as log (10^4 neutrophil/mL).</description>
          <population>The change in neutrophil cell count from Day 1 to Day 28 was performed using a Kruskal-Wallis equality of populations rank test. The cells counts are expressed as log 10 (neutrophil cell/mL).</population>
          <units>log 10 (neutrophil cell/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="-0.24" upper_limit="0.82"/>
                    <measurement group_id="O2" value="-0.26" lower_limit="-0.41" upper_limit="0.29"/>
                    <measurement group_id="O3" value="-0.02" lower_limit="-0.33" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in C Reactive Protein (CRP) During Treatment.</title>
        <description>Median changes in CRP and IQR were assessed from serum samples collected at Visits 1,3, 4 and 5.</description>
        <time_frame>Baseline and Day 28</time_frame>
        <population>All subjects had blood labs for CRP drawn on Visits 1,3,4 and 5. The changes in median CRP were calculated during the Treatment Period (28 days).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in C Reactive Protein (CRP) During Treatment.</title>
          <description>Median changes in CRP and IQR were assessed from serum samples collected at Visits 1,3, 4 and 5.</description>
          <population>All subjects had blood labs for CRP drawn on Visits 1,3,4 and 5. The changes in median CRP were calculated during the Treatment Period (28 days).</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" lower_limit="-0.50" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.00" upper_limit="0.40"/>
                    <measurement group_id="O3" value="-0.05" lower_limit="-0.20" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Erythrocyte Sedimentation Rate (ESR) During Treatment Period.</title>
        <description>Median change in serum ESR (mm/hr) and IQR was calculated from Treatment Period (28 days).</description>
        <time_frame>Baseline and Day 28</time_frame>
        <population>All subjects had blood labs for ESR drawn on Visits 1,3,4 and 5. The changes in median ESR were calculated during the Treatment Period (28 days).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Erythrocyte Sedimentation Rate (ESR) During Treatment Period.</title>
          <description>Median change in serum ESR (mm/hr) and IQR was calculated from Treatment Period (28 days).</description>
          <population>All subjects had blood labs for ESR drawn on Visits 1,3,4 and 5. The changes in median ESR were calculated during the Treatment Period (28 days).</population>
          <units>mm/hr</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-5.50" upper_limit="0.50"/>
                    <measurement group_id="O2" value="3.50" lower_limit="0.05" upper_limit="11.50"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-3.50" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of CF Subjects With Microarray Results From Nasal Epithelial Cells to Measure the Effect of Digitoxin on Gene Expression.</title>
        <description>Rhinoprobe was used to collect nasal epithelial cells. The cells were collected pre and post-treatment and placed in Trizol for RNA isolation then used to measure the effect of digitoxin on gene expression. The full set of microarray data has been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). The accession number for that data is GSE76347 (data available Dec 2018).</description>
        <time_frame>Day 0 and Day 28</time_frame>
        <population>The full set of microarray data has been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). Results can be found under the accession number GSE76347. One subject's pair of specimens in the placebo group was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All study participants had nasal cells collected pre and post treatment during the study. Because the data set is extremely large, the full set of microarray data has been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) this information can be obtained under the accession number.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CF Subjects With Microarray Results From Nasal Epithelial Cells to Measure the Effect of Digitoxin on Gene Expression.</title>
          <description>Rhinoprobe was used to collect nasal epithelial cells. The cells were collected pre and post-treatment and placed in Trizol for RNA isolation then used to measure the effect of digitoxin on gene expression. The full set of microarray data has been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). The accession number for that data is GSE76347 (data available Dec 2018).</description>
          <population>The full set of microarray data has been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). Results can be found under the accession number GSE76347. One subject's pair of specimens in the placebo group was not collected.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Alterations in ECG Readings</title>
        <description>Safety indices included an assessment for the number of clinically significant alterations in the subjects ECG readings from Day 1 to Day 28.</description>
        <time_frame>28 days</time_frame>
        <population>Count of clinically significant alterations in the ECG in all subjects during the Treatment Phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Alterations in ECG Readings</title>
          <description>Safety indices included an assessment for the number of clinically significant alterations in the subjects ECG readings from Day 1 to Day 28.</description>
          <population>Count of clinically significant alterations in the ECG in all subjects during the Treatment Phase of the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Changes in the Microbiology of Sputum in Subjects</title>
        <description>Count of clinically significant changes in sputum microbiology during the Treatment phase (Day 1 to Day 28) to include any new acquisition of B. cepacia or new acquisition of any multiple resistant organism.</description>
        <time_frame>28 days</time_frame>
        <population>There were no significant changes in the microbiology of sputum in any subjects over the course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.05mg Digitoxin</title>
            <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Higher Dose 0.1mg Digitoxin</title>
            <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Changes in the Microbiology of Sputum in Subjects</title>
          <description>Count of clinically significant changes in sputum microbiology during the Treatment phase (Day 1 to Day 28) to include any new acquisition of B. cepacia or new acquisition of any multiple resistant organism.</description>
          <population>There were no significant changes in the microbiology of sputum in any subjects over the course of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Screening through Day 42 or the Early Withdraw Visit.</time_frame>
      <desc>Physical exams by study physician at each visit and documented in the subject case report forms. All Adverse Events were subsequently followed up until resolution.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo given daily for 28 days
placebo: pill taken once daily for 28 days</description>
        </group>
        <group group_id="E2">
          <title>Low Dose 0.05 mg Digitoxin</title>
          <description>low dose 0.05mg digitoxin given once daily for 28 days
digitoxin: 0.05mg tabs, once daily for 28 days</description>
        </group>
        <group group_id="E3">
          <title>Higher Dose 0.1mg Digitoxin</title>
          <description>higher dose 0.1mg digitoxin daily for 28 days
digitoxin: 0.1mg pills, once daily for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>vaginal yeast infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>erythema, nares</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>pain, nares</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>tonic clonic seizure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased urination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>menstrual cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>crackles</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>decrease breath sounds</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>decreased lung function</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>increased sputum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>pulmonary exacerbation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>rhonchi</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>wheeze</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Steady states of digitoxin were not achieved in subjects until relatively late the in 28 day treatment period. This would suggest that it may require a much longer treatment course to meaningfully effect inflammation in the airways.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pamela L. Zeitlin, M.D., Ph.D., Professor and Director of SOM Pediatric Pulmonary</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>443-287-8981</phone>
      <email>pzeitlin@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

